TFF Pharmaceuticals Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

TFF Pharmaceuticals has a total shareholder equity of $5.9M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $9.5M and $3.6M respectively.

Belangrijke informatie

Verhouding schuld/eigen vermogen

US$0

Schuld

Rente dekkingsratio	n/a
Contant	US$4.39m
Aandelen	US$5.88m
Totaal verplichtingen	US$3.62m
Totaal activa	US$9.50m

Recente financiële gezondheidsupdates

Can TFF Pharmaceuticals (NASDAQ:TFFP) Afford To Invest In Growth?

Apr 10

Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?

Sep 27

We Think TFF Pharmaceuticals (NASDAQ:TFFP) Needs To Drive Business Growth Carefully

May 17

Here's Why We're Not Too Worried About TFF Pharmaceuticals' (NASDAQ:TFFP) Cash Burn Situation

Jan 06

Recent updates

Can TFF Pharmaceuticals (NASDAQ:TFFP) Afford To Invest In Growth?

Apr 10

Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?

Sep 27

We Think TFF Pharmaceuticals (NASDAQ:TFFP) Needs To Drive Business Growth Carefully

May 17

Here's Why We're Not Too Worried About TFF Pharmaceuticals' (NASDAQ:TFFP) Cash Burn Situation

Jan 06

TFF Pharmaceuticals: Upside Catalysts Starting To Show Up Amid Omicron, But Timidly

Dec 02

Analyse van de financiële positie

Kortlopende schulden: TFFP's short term assets ($5.9M) exceed its short term liabilities ($3.6M).

Langlopende schulden: TFFP has no long term liabilities.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: TFFP is debt free.

Schuld verminderen: TFFP has not had any debt for past 5 years.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: TFFP has less than a year of cash runway based on its current free cash flow.

Voorspelling contante baan: TFFP has less than a year of cash runway if free cash flow continues to reduce at historical rates of 21.9% each year

TFF Pharmaceuticals Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Can TFF Pharmaceuticals (NASDAQ:TFFP) Afford To Invest In Growth?

Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?

We Think TFF Pharmaceuticals (NASDAQ:TFFP) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About TFF Pharmaceuticals' (NASDAQ:TFFP) Cash Burn Situation

Recent updates

New major risk - Share price stability

New major risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 77%

TFF Pharmaceuticals, Inc. Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant Rejection

Tff Pharmaceuticals, Inc. Provides Regulatory Update on Tacrolimus Inhalation Powder (Tff Tac) Clinical Program for the Prevention of Lung Transplant Rejection

Consensus revenue estimates decrease by 29%, EPS upgraded

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $2.055 million.

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Tff Pharmaceuticals, Inc. Provides Update on Tacrolimus Inhalation Powder (Tff Tac) Phase 2 Trial for the Prevention of Lung Transplant Rejection

TFF Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.787396 million.

TFF Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.787396 million.

TFF Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $4.787505 million.

TFF Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2024

TFF Pharmaceuticals, Inc. Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF Tac) Phase 2 Trial Following Oral Presentation At the Ishlt 44Th Annual Late-Breaking Clinical Science Abstract Sessions

New major risk - Market cap size

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 39%

No longer forecast to breakeven

TFF Pharmaceuticals, Inc. Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (Tff VORI) Clinical Programs

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.18 million.

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.18 million.

TFF Pharmaceuticals, Inc. Announces Update on Clinical Programs

New major risk - Share price stability

TFF Pharmaceuticals, Inc. to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder for the Treatment of Invasive Pulmonary Aspergillosis At the 11Th Advances Against Aspergillosis & Mucormycosis & Mucromycosis Conference

Forecast to breakeven in 2026

New minor risk - Profitability

TFF Pharmaceuticals, Inc. Appoints Thomas B. King to Board of Directors

TFF Pharmaceuticals, Inc. Appoints Catherine Lee to its Board of Directors

TFF Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $35 million.

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 40%

TFF Pharmaceuticals, Inc., Annual General Meeting, Nov 21, 2023

Aaron Fletcher Advises TFF Pharmaceuticals, Inc. of His Decision Not to Stand for Reelection to the Board

Consensus revenue estimates increase by 37%

New major risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 21%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Can TFF Pharmaceuticals (NASDAQ:TFFP) Afford To Invest In Growth?

No longer forecast to breakeven

No longer forecast to breakeven

Key Executive recently bought US$132k worth of stock

Consensus revenue estimates increase by 16%

TFF Pharmaceuticals, Inc. Appoints Harlan Weisman, M.D. as Permanent Chief Executive Officer

TFF Pharmaceuticals, Inc. Appoints Zamaneh Mikhak as Chief Medical Officer

Forecast to breakeven in 2025

Key Executive recently bought US$53k worth of stock

TFF Pharmaceuticals Announces Leadership Transition

Consensus revenue estimates increase by 98%

Third quarter 2022 earnings released: US$0.29 loss per share (vs US$0.34 loss in 3Q 2021)

High number of new and inexperienced directors

Price target decreased to US$16.00

TFF Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

TFF Pharmaceuticals, Inc. Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder Through Compassionate Use Program

TFF Pharmaceuticals Announces Presentation of Data Featuring Applications of Thin Film Freezing Technology at AAPS PharmSci 360 Meeting

Independent Director exercised options and sold US$72k worth of stock

Is TFF Pharmaceuticals (NASDAQ:TFFP) In A Good Position To Deliver On Growth Plans?

TFF Pharmaceuticals Announces Acceptance of Multiple Abstracts Featuring Applications of Thin Film Freezing Technology at the Upcoming AAPS PharmSci 360 Meeting

TFF Pharmaceuticals, Inc., Annual General Meeting, Nov 07, 2022

TFF Pharmaceuticals, Inc. Announces Presentation of Patient Data with Voriconazole Inhalation Powder At the 15Th International Congress on Lung Transplantation

TFF Pharma: The Potential Is Still Very Much Present

Consensus revenue estimates fall by 84%

No longer forecast to breakeven

No longer forecast to breakeven

Second quarter 2022 earnings released: US$0.34 loss per share (vs US$0.18 loss in 2Q 2021)

TFF Pharmaceuticals: Q3 Data Is Pivotal In So Many Ways

TFF Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

TFF Pharmaceuticals expands R&D operations with new Austin facility

TFF Pharmaceuticals: A Highly Attractive Basket Of Options